| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Treatment of glioblastoma cells with tyrophostin AG1433 (0.1-100 μM; 72 hours; GB8B cells) causes moderate cytotoxicity [1].
|
|---|---|
| ln Vivo |
Angiogenesis was examined using the Chorioallantoic membrane (CAM) assay to evaluate the impact of Flk-i inhibitors. Tyrphostin AG1433 (SU1433) is suited for CAM in chicken embryos that are 4-6 days old and is made from methylcellulose particles. Under the particles, tyrosine phosphatase AG1433 inhibits the growth of new fish algae [2].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: GB8B Cell Tested Concentrations: 0.1 μM, 1 μM, 5 μM, 10 μM, 20 μM, 30 μM, 50 μM, 60 μM, 100 μM Incubation Duration: 72 hrs (hours) Experimental Results: Significant induction Cell death occurred in a concentration-dependent manner in GB8B cells. |
| References | |
| Additional Infomation |
Tyrphostin AG 1433 is a member of the Tyrphostin family of tyrosine kinase inhibitors that selectively inhibits platelet-derived growth factor beta-receptor kinase and angiogenesis. (NCI)
|
| Molecular Formula |
C16H14N2O2
|
|---|---|
| Molecular Weight |
266.29456
|
| Exact Mass |
266.105
|
| CAS # |
168835-90-3
|
| PubChem CID |
2050
|
| Appearance |
Light yellow to khaki solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC2=NC=C(N=C2C=C1C)C3=CC(=C(C=C3)O)O
|
| InChi Key |
SMKFYHOKXJUJOT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2O2/c1-9-5-12-13(6-10(9)2)18-14(8-17-12)11-3-4-15(19)16(20)7-11/h3-8,19-20H,1-2H3
|
| Chemical Name |
4-(6,7-dimethylquinoxalin-2-yl)benzene-1,2-diol
|
| Synonyms |
Tyrphostin AG1433; Tyrphostin AG-1433
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~234.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7553 mL | 18.7765 mL | 37.5530 mL | |
| 5 mM | 0.7511 mL | 3.7553 mL | 7.5106 mL | |
| 10 mM | 0.3755 mL | 1.8777 mL | 3.7553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
